AW
NBIX icon

Avion Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Avion Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1K Sell
11
-6
-35% -$964 ﹤0.01% 1275
2026
Q2 		$2K Buy
17
+9
+113% +$1.34K ﹤0.01% 1097
2026
Q1 		$1K Hold
8
– – ﹤0.01% 1092
2025
Q4 		$1K Sell
8
-4
-33% -$579 ﹤0.01% 1084
2025
Q3 		$1K Buy
12
+4
+50% +$542 ﹤0.01% 1060
2025
Q2 		$1K Sell
8
-8
-50% -$917 ﹤0.01% 1016
2025
Q1 		$2K Hold
16
– – ﹤0.01% 749
2024
Q4 		$2K Sell
16
-2
-11% -$247 ﹤0.01% 746
2024
Q3 		$2K Sell
18
-8
-31% -$1.1K ﹤0.01% 703
2024
Q2 		$3K Buy
26
+4
+18% +$549 ﹤0.01% 565
2024
Q1 		$4K Buy
22
+12
+120% +$1.64K ﹤0.01% 512
2023
Q4 		$1K Sell
10
-10
-50% -$1.15K ﹤0.01% 887
2023
Q3 		$2K Buy
+20
New +$2.11K ﹤0.01% 504

Other funds holding NBIX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $102B AUM 35.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Avion Wealth's NBIX Position: Q3 2026 in Review

Avion Wealth reduced its Neurocrine Biosciences (NBIX) stake by 35% in Q3 2026, selling an estimated $964 and leaving 11 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1275.

Avion Wealth first reported a position in NBIX in Q3 2023 and has held it in 13 quarters since. The position peaked at $4K in Q1 2024. 630 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Avion Wealth held 11 shares of Neurocrine Biosciences worth $1K as of Q3 2026.
  • Avion Wealth sold 6 Neurocrine Biosciences shares in Q3 2026, an estimated $964.
  • Neurocrine Biosciences made up ﹤0.01% of Avion Wealth's portfolio in Q3 2026, its #1275 holding.
  • Avion Wealth first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 13 quarters since.
  • Avion Wealth's Neurocrine Biosciences position peaked at $4K in Q1 2024.
  • 630 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Avion Wealth's 13F filing for Q3 2026, filed 4 Nov 2026.